Company news
Atea Pharmaceuticals, Inc. news in 2022
Atea Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
November 28, 2022
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 6, 2022
Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
November 2, 2022
Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022
October 30, 2022
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue
September 25, 2022
Atea Pharmaceuticals Announces Upcoming Investor Events
September 6, 2022
Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 7, 2022
Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022
July 31, 2022
Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on May 10, 2022
May 2, 2022
Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting
March 27, 2022
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 27, 2022
Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development
February 9, 2022
Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir’s (AT-527) Novel Mechanism of Action Against SARS-CoV-2 in Nature Communications
February 1, 2022
Atea Pharmaceuticals Highlights Strategic Priorities for 2022
January 6, 2022
Calls in 2022
Decks in 2022
- JP Morgan Healthcare Conference 2022
Conference · 28 slides · Jan 10, 2022